1. Home
  2. FSEA vs RLYB Comparison

FSEA vs RLYB Comparison

Compare FSEA & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Seacoast Bancorp Inc.

FSEA

First Seacoast Bancorp Inc.

HOLD

Current Price

$17.17

Market Cap

79.2M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$16.79

Market Cap

89.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSEA
RLYB
Founded
1890
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
89.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
FSEA
RLYB
Price
$17.17
$16.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.0K
11.5K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
6.16
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.75
Revenue Growth
N/A
43.00
52 Week Low
$11.08
$0.48
52 Week High
$17.21
$17.57

Technical Indicators

Market Signals
Indicator
FSEA
RLYB
Relative Strength Index (RSI) 70.87 59.20
Support Level $16.84 $16.51
Resistance Level $17.21 $17.32
Average True Range (ATR) 0.03 0.42
MACD -0.00 -0.01
Stochastic Oscillator 93.75 73.68

Price Performance

Historical Comparison
FSEA
RLYB

About FSEA First Seacoast Bancorp Inc.

First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: